Early Residual Fluid-free Status and Long-term BCVA outcomes: A Treatment Agnostic, Post-hoc Analysis of Pooled HAWK and HARRIER Data.

Abstract

PURPOSE\nDetermine associations between early residual fluid (ERF)-free status and improved long-term visual outcomes.\n\n\nDESIGN\nClinical cohort study from post hoc analysis of two phase 3 clinical trials data.\n\n\nMETHODS\nIndependent of treatment allocation, patients from the multicenter, prospective, randomized, double-masked HAWK and HARRIER trials who received either brolucizumab 6 mg or aflibercept 2 mg were split into two cohorts dependent on presence or absence of ERF at week 12. Additionally, similar analyses were performed on presence or absence of early residual intraretinal fluid (IRF) and subretinal fluid (SRF) at week 12. The two groups, ERF-free (N=1051) and ERF (N=366) were compared. Changes from baseline in best-corrected visual acuity (BCVA) and central subfield thickness (CST) were determined.\n\n\nRESULTS\nFrom week 12 to 96, patients who were ERF-free had greater least square (LS) mean increases from baseline for BCVA and CST compared to ERF patients. Greater LS mean differences in BCVA from week 12 to 96 were noted between ERF-free and ERF patients. A greater proportion of patients in the ERF-free cohort reported a ≥5, ≥10, or ≥15 letter improvement and a higher proportion reported BCVA ≥70 letters from baseline to week 96 compared to those with fluid.\n\n\nCONCLUSIONS\nImprovements in visual outcomes in ERF-free patients were greater than in ERF patients occurring as early as 4 weeks (week 12) following the last loading dose and continued to week 96. Therefore, ERF status may be a useful indicator of anti-vascular endothelial growth factor treatment response.